Tissue Collection Protocol for Gastroesophageal Cancers (NCT02495337)
Tissue Collection for Gastro-esophageal Cancer Primary Cell Line Establishment
🩺 Plain-English Summary (8th-Grade Level)
This proposed collection of primary tumor cells lines will benefit esophageal cancer research within the University Health Network. This collection of gastro-esophageal tumor samples will be used to grow primary tumor cell lines, which will provide researchers with ready samples of various gastro-esophageal cancers. This will help to address the issue of access to these cell lines due to the limited number of patients with gastro-esophageal tumors, and high rates of contamination.
Who can join: Review the eligibility criteria below.
Location: University Health Network: Toronto General Hospital — Toronto, Ontario
Age range: 18 Years
🧪 Interventions in This Study
- Tissue Collection (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University Health Network: Toronto General Hospital — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (416) 340-5446
Email: Frances.Allison@uhn.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Esophageal Cancer
- Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer — Philadelphia, Pennsylvania
- Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial — Houston, Texas
- Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors — Los Angeles, California
- Genetic and Environmental Risk Factors Related to Esophageal Cancer — Boston, Massachusetts
- Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer — Winnipeg, Manitoba
- Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract — New York, New York
Explore by condition: All Esophageal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.